Drug Description in Trials / DrugBank / KEGG DRUG /


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide----1件: 11
2250 mg CK-2017357----2件: 2, 11
3500 mg CK-2017357----2件: 2, 11
4Abatacept1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
5Abatacept Injection1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬2件: 11, 46
6Acetaminophen1件: Acetaminophen1件: D00217 2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬13件: 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337
7Acetominofene----2件: 11, 63
8ALN-CC5----4件: 11, 62, 66, 109
9Aluminium1件: Aluminium---2件: 11, 46
10Aluminium hydroxide3件: Aluminium,
Aluminum hydroxide,
Hydroxide ion
1件: D02416 --2件: 11, 46
11Aluminum1件: Aluminium---1件: 11
12Aluminum hydroxide3件: Aluminium,
Aluminum hydroxide,
Hydroxide ion
1件: D02416 --1件: 11
13ALXN1210----7件: 2, 11, 13, 50, 62, 66, 109
14ALXN1830----3件: 11, 35, 61
15ALXN2050----2件: 11, 62
16AMIFAMPRIDINA----2件: 3, 11
17Amifampridina fosfato----2件: 3, 11
18Amifampridine1件: Amifampridine1件: D10228 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬
4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬3件: 3, 11, 12
19Amifampridine Phosphate2件: Amifampridine,
Phosphate ion
1件: D10228 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬
4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬3件: 3, 11, 12
20Anti-C5 antibody----4件: 11, 14, 62, 109
21Anti-Thymocyte Globulin----18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285
22Apraclonidine1件: Apraclonidine1件: D07461 3件: ADRA2A,
ADRA2B,
ADRA2C 💬
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 11
23Apraclonidine Hcl 0.5% Oph Soln1件: Apraclonidine1件: D07461 3件: ADRA2A,
ADRA2B,
ADRA2C 💬
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 11
24ARGX-113----5件: 11, 14, 35, 53, 63
25ATG (rabbit)1件: Rabbit---1件: 11
26AZA----4件: 11, 40, 96, 97
27Azathioprine1件: Azathioprine1件: D00238 --21件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162
28B-peptide-CRM197 conjugate1件: Corynebacterium diphtheriae CRM197 protein---1件: 11
29Balance1件: Isoxaflutole---5件: 6, 11, 46, 81, 149
30Batoclimab1件: Batoclimab1件: D11983 1件: FCGRT 💬-2件: 11, 14
31Batoclimab 340 mg SC bi-weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-1件: 11
32Batoclimab 340 mg SC weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-2件: 11, 14
33Batoclimab 680 mg SC weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-1件: 11
34BBR 2778----2件: 11, 13
35BELIMUMAB1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300
36Benlysta (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬4件: 11, 49, 53, 222
37BENLYSTA® (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬3件: 11, 66, 222
38Bexsero1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---6件: 11, 13, 61, 62, 66, 222
39BORTEZOMIB1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬17件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331
40Carmustine1件: Carmustine1件: D00254 --5件: 11, 13, 14, 28, 60
41CD19-directed humanised afucosylated monoclonal antibody----1件: 11
42CELLCEPT----5件: 11, 13, 42, 43, 49
43CellCept 500 mg----1件: 11
44CellCept 500 mg film-coated tablets1件: Mycophenolate mofetil1件: D00752 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 11
45CellCept 500 mg tablets1件: Mycophenolate mofetil1件: D00752 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 11
46CellCept®500 mg tablets1件: Mycophenolate mofetil1件: D00752 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 11
47Cemdisiran1件: Cemdisiran---4件: 11, 62, 66, 109
48CFZ533----4件: 11, 46, 49, 53
49Chloride1件: Chloride ion---28件: 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 288, 296, 297, 299, 338
50CLADRIBINE1件: Cladribine1件: D01370 1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬3件: 11, 13, 94
51Cladrybine----1件: 11
52Corynebacterium diphtheriae1件: Corynebacterium diphtheriae---1件: 11
53CRM1971件: Corynebacterium diphtheriae CRM197 protein---3件: 11, 13, 46
54CT103A cells----2件: 11, 13
55CV-MG011件: CV-MG01---1件: 11
56Cyclophosphamide1件: Cyclophosphamide2件: D00287 ,
D07760
--44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331
57Cyclophosphamide and fludarabine2件: Cyclophosphamide,
Fludarabine
3件: D00287 ,
D07760 ,
D07966
1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬2件: 11, 13
58Cyclosporine1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬37件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302
59Cytarabine1件: Cytarabine1件: D00168 --7件: 11, 13, 14, 25, 49, 60, 65
60DAS-001----1件: 11
61Descartes-08----1件: 11
62Difenidramina----2件: 11, 63
63DIFENIDRAMINA CLORIDRATO----3件: 11, 19, 63
64Diphenhydramine1件: Diphenhydramine1件: D00300 1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬8件: 11, 13, 49, 51, 70, 86, 222, 256
65Diphenhydramine hydrochloride1件: Diphenhydramine1件: D00300 1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬2件: 11, 49
66ECULIZUMAB1件: Eculizumab1件: D03940 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 11, 13, 14, 61, 62, 109, 222
67EFALIZUMAB1件: Efalizumab1件: D03959 1件: ITGAL 💬12件: Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬8件: 11, 13, 37, 46, 53, 61, 95, 96
68Efedrina1件: Ephedrine1件: D00124 9件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3 💬
14件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
69Efgartigimod----4件: 11, 35, 53, 63
70EFGARTIGIMOD ALFA1件: Efgartigimod alfa1件: D11876 1件: FCGRT 💬-6件: 11, 14, 35, 53, 63, 162
71Efgartigimod concentrate for solution for infusion 20 mg/mL----1件: 11
72Efgartigimod IV----1件: 11
73Efgartigimod PH20 SC----5件: 11, 14, 35, 63, 162
74EN101----1件: 11
75Ephedrine1件: Ephedrine1件: D00124 9件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3 💬
14件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
76EPHEDRINE HYDROCHLORIDE1件: Ephedrine1件: D00124 9件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3 💬
14件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
77Etoposide1件: Etoposide1件: D00125 2件: TOP2A,
TOP2B 💬
1件: Platinum drug resistance 💬11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
78Famciclovir1件: Famciclovir1件: D00317 --2件: 11, 13
79Fc- and CDR-modified humanised monoclonal antibody against C5----3件: 11, 62, 109
80Firdapse1件: Amifampridine1件: D10228 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬
4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬2件: 3, 11
81FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE1件: Amifampridine1件: D10228 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬
4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬2件: 3, 11
82Fludarabine1件: Fludarabine1件: D07966 1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬19件: 11, 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
83Fusion1件: Iron polymaltose---7件: 11, 13, 46, 49, 69, 70, 271
84G-CSF1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬16件: 2, 6, 11, 13, 16, 22, 47, 51, 60, 62, 65, 85, 96, 284, 285, 331
85GAMUNEX 10%1件: Human immunoglobulin G---1件: 11
86GB-0998 (Intravenous immunoglobulin)----1件: 11
87Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms----1件: 11
88Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)----1件: 11
89GSK1550188----4件: 11, 49, 66, 222
90HBM9161 Injection (340 mg)----1件: 11
91HBM9161 Injection (680mg and 340 mg)----1件: 11
92HBM9161 Injection (680mg)----1件: 11
93Hematopoietic Stem Cell Transplantation----12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285
94Hidrocloruro de efedrina1件: Ephedrine1件: D00124 9件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3 💬
14件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
95HIZENTRA ®----1件: 11
96Human normal immunoglobulin1件: Human immunoglobulin G---9件: 11, 13, 14, 43, 45, 50, 51, 63, 65
97HUMAN NORMAL IMMUNOGLOBULIN (IV)1件: Human immunoglobulin G---4件: 11, 14, 63, 65
98Human normal immunoglobulin G (IgG)1件: Human immunoglobulin G---1件: 11
99Hydroxide1件: Hydroxide ion---5件: 11, 46, 96, 97, 284
100IGIV-C----1件: 11
101Immune globulin----3件: 11, 13, 14
102Immune Globulin (Human), 10% Caprylate/Chromatography Purified1件: Human immunoglobulin G---1件: 11
103Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C)1件: Human immunoglobulin G---1件: 11
104IMMUNOGLOBULIN G----8件: 2, 11, 13, 14, 49, 50, 63, 65
105INEBILIZUMAB1件: Inebilizumab1件: D11757 1件: CD19 💬5件: B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬4件: 11, 13, 51, 300
106Influenza vaccine----5件: 11, 13, 46, 51, 84
107Intravenous ImmuneGlobulin----1件: 11
108Intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)----1件: 11
109IVIG1件: Human immunoglobulin G---7件: 11, 13, 14, 17, 50, 51, 65
110JNJ-80202135----4件: 11, 46, 49, 53
111Leflunomide1件: Leflunomide1件: D00749 1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬12件: 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300
112M281----5件: 11, 46, 49, 53, 61
113M281 Injection----1件: 11
114MabThera1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271
115Magnesium1件: Magnesium---15件: 6, 11, 46, 64, 70, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298
116Magnesium sulfate3件: Magnesium gluconate,
Magnesium sulfate,
Sulfate ion
2件: D01108 ,
D04835
--3件: 11, 296, 297
117Melphalan1件: Melphalan1件: D00369 --15件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299
118MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN2件: Corynebacterium diphtheriae,
Corynebacterium diphtheriae CRM197 protein
---1件: 11
119MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN2件: Corynebacterium diphtheriae,
Corynebacterium diphtheriae CRM197 protein
---1件: 11
120MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN2件: Corynebacterium diphtheriae,
Corynebacterium diphtheriae CRM197 protein
---1件: 11
121MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN2件: Corynebacterium diphtheriae,
Corynebacterium diphtheriae CRM197 protein
---1件: 11
122MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN2件: Corynebacterium diphtheriae,
Corynebacterium diphtheriae CRM197 protein
---1件: 11
123Menveo1件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine---6件: 11, 13, 61, 62, 66, 222
124Mesna1件: Coenzyme M---10件: 11, 13, 44, 45, 51, 60, 65, 85, 96, 164
125Mestinon1件: Pyridostigmine---3件: 3, 6, 11
126Methotrexate1件: Methotrexate1件: D00142 2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
127Methylprednisolone1件: Methylprednisolone1件: D00407 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
128Metilprdnisolone----1件: 11
129METILPREDNISOLONE----6件: 11, 13, 53, 56, 63, 300
130MG-O-1002----1件: 11
131MONARSEN1件: Monarsen---1件: 11
132MONITOR1件: Methamidophos---4件: 2, 11, 81, 129
133MuSK-CAART----1件: 11
134Mutagrip----2件: 11, 13
135Mycophenolate1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
136Mycophenolate mofetil2件: Mycophenolate mofetil,
Mycophenolic acid
2件: D00752 ,
D05096
2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
137Mycophenolate mofetil (CellCept)2件: Mycophenolate mofetil,
Mycophenolic acid
2件: D00752 ,
D05096
2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬2件: 11, 13
138Mycophenolate mofetil [CellCept]2件: Mycophenolate mofetil,
Mycophenolic acid
2件: D00752 ,
D05096
2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 11
139Mycophenolic acid1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬8件: 11, 43, 49, 51, 60, 66, 96, 222
140N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO----1件: 11
141N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE5件: Aluminium,
Aluminum hydroxide,
Corynebacterium diphtheriae,
Corynebacterium diphtheriae CRM197 protein,
Hydroxide ion
1件: D02416 --1件: 11
142Nipocalimab1件: Nipocalimab1件: D11666 1件: FCGRT 💬-6件: 11, 14, 46, 49, 53, 61
143Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4----1件: 11
144Oxaloacetate1件: Oxaloacetic acid---2件: 6, 11
145PARACETAMOLO----9件: 2, 11, 14, 19, 28, 53, 61, 63, 300
146Phosphate1件: Phosphate ion---32件: 2, 3, 6, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299
147PIXANTRONE1件: Pixantrone1件: D05522 2件: TOP2A,
TOP2B 💬
1件: Platinum drug resistance 💬2件: 11, 13
148Placebo----28件: 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276
149Pozelimab1件: Pozelimab1件: D11477 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 11, 62
150Pozelimab + Cemdisiran2件: Cemdisiran,
Pozelimab
1件: D11477 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 11
151PREDNISOLONE1件: Prednisolone1件: D00472 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬42件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300
152Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331
153Prednisone - Azathioprine2件: Azathioprine,
Prednisone
2件: D00238 ,
D00473
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 11
154Prednisone alone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 11, 66
155PRIVIGEN1件: Human immunoglobulin G---4件: 11, 14, 51, 65
156PRN2246----2件: 11, 13
157Pyridostigmine1件: Pyridostigmine---4件: 3, 6, 11, 256
158Pyridostigmine, Prednisone, Tacrolimus3件: Prednisone,
Pyridostigmine,
Tacrolimus
3件: D00107 ,
D00473 ,
D08556
6件: NR3C1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
159Pyridostigmine, Tacrolimus2件: Pyridostigmine,
Tacrolimus
2件: D00107 ,
D08556
5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
160Rabbit1件: Rabbit---8件: 11, 13, 49, 51, 60, 65, 96, 285
161Raptiva1件: Efalizumab1件: D03959 1件: ITGAL 💬12件: Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬9件: 11, 13, 37, 46, 49, 53, 61, 95, 96
162Raptiva 100 mg/ml powder and solvent for solution for injection1件: Efalizumab1件: D03959 1件: ITGAL 💬12件: Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬7件: 11, 13, 46, 53, 61, 95, 96
163RAVULIZUMAB1件: Ravulizumab1件: D11054 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 2, 11, 13, 50, 62, 66, 109
164RC18 160mg----3件: 11, 13, 66
165RC18 240 mg----2件: 11, 53
166RECOMBINANT NEISSERIA----1件: 11
167RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E.COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE4件: Aluminium,
Aluminum hydroxide,
Hydroxide ion,
Iron polymaltose
1件: D02416 --1件: 11
168RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN----1件: 11
169RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN1件: Iron polymaltose---2件: 11, 13
170REGN3918----2件: 11, 62
171RITUXIMAB1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
172Rituximab (Rituxan)1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 11
173Ro 533-3787/F01-06----1件: 11
174RO5333787----2件: 11, 13
175ROZANOLIXIZUMAB1件: Rozanolixizumab1件: D12182 1件: FCGRT 💬-3件: 11, 14, 63
176RTX----5件: 11, 46, 65, 222, 240
177RVT-1401----2件: 11, 61
178Salbutamol1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬8件: 3, 11, 49, 85, 86, 111, 256, 299
179Salbutamol 4Mg Tablet1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
180SALBUTAMOL SULFATE PH. EUR.2件: Salbutamol,
Sulfate ion
1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
181Salbutamol WZF 4 mg1件: Salbutamol1件: D02147 1件: ADRB2 💬9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
182SAR442168----2件: 11, 13
183SATRALIZUMAB1件: Satralizumab1件: D11079 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 11, 13, 86
184Sodium chloride2件: Chloride ion,
Sodium chloride
1件: D02056 --20件: 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 168, 193, 227, 228, 288, 299
185Sodium Chloride solution2件: Chloride ion,
Sodium chloride
1件: D02056 --4件: 11, 13, 51, 228
186SOLIRIS1件: Eculizumab1件: D03940 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 11, 13, 14, 61, 62, 109, 222
187Subcutaneous immunoglobulin (SCIG)----1件: 11
188Subcutaneous immunoglobulins----1件: 11
189Sulfate1件: Sulfate ion---27件: 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 85, 86, 96, 111, 218, 222, 224, 226, 265, 296, 297, 299
190Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)1件: Human immunoglobulin G---1件: 11
191T-peptide-CRM197 conjugate1件: Corynebacterium diphtheriae CRM197 protein---1件: 11
192Tacrolimus1件: Tacrolimus2件: D00107 ,
D08556
5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
193Tacrolimus capsule1件: Tacrolimus2件: D00107 ,
D08556
5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
194TAK-079----3件: 11, 49, 63
195TAK-079, TSF-021, TSF79----1件: 11
196Tetanus vaccin----1件: 11
197Tocilizumab1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
198Tocilizumab Injectable Product1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 11
199Tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
200Tofacitinib 5 MG1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬4件: 11, 40, 46, 271
201Tolebrutinib----2件: 11, 13
202Tolebrutininb----1件: 11
203UCB7665----3件: 11, 14, 63
204Ultomiris1件: Ravulizumab1件: D11054 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬6件: 2, 11, 13, 50, 62, 66
205Ultomiris 1,100 mg/11 mL1件: Ravulizumab1件: D11054 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬1件: 11
206Uplizna1件: Inebilizumab1件: D11757 1件: CD19 💬5件: B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬2件: 11, 300
207Velamox----1件: 11
208Velcade1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬3件: 11, 28, 61
209Velcade®1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 11
210Zilucoplan1件: Zilucoplan1件: D12357 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬3件: 2, 11, 62
211Zilucoplan (RA101495)1件: Zilucoplan1件: D12357 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 11, 62